Noopept
clinical trialsAlso known as: Omberacetam, GVS-111
**Mechanism of Action** Noopept (Omberacetam, GVS-111) is a synthetic proline-containing dipeptide that functions as a prodrug for cycloprolylglycine (CPG). Its primary mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and cortex, promoting synaptic plasticity and neuronal survival. Additionally, it modulates cholinergic and glutamatergic systems, including AMPA receptor trafficking, and exhibits antioxidant and anti-inflammatory properties. These actions underlie its nootropic (cognitive-enhancing) and anxiolytic effects, distinguishing it from classical racetam compounds. **Key Research Findings** Clinical trials and preclinical studies demonstrate Noopept’s ability to improve memory, attention, and learning in models of cognitive impairment (e.g., scopolamine-induced amnesia, chronic stress). It shows dose-dependent neuroprotection against excitotoxicity and oxidative stress, with oral bioavailability and rapid brain penetration. Human trials report enhanced cognitive performance in healthy adults and reduced anxiety in stress-related conditions, though effect sizes vary. Animal studies also indicate potential for stroke recovery and age-related cognitive decline, with a favorable safety profile at therapeutic doses (10–30 mg/day). **Clinical Relevance** Noopept is investigated for cognitive enhancement in healthy individuals and as an adjunctive therapy for mild cognitive impairment, post-stroke recovery, and anxiety disorders. Its rapid onset and low toxicity profile make it a candidate for chronic use, though long-term human data remain limited. Regulatory status varies by country; it is not FDA-approved for medical use. Further randomized controlled trials are needed to confirm efficacy and safety in specific clinical populations. For research purposes only — not medical advice.
Key data
C17H22N2O4Research & studies
Natural compounds like curcumin, Ginkgo biloba, and Panax ginseng show cognitive benefits with ongoing research into nanoformulation delivery.; Synthetic enhancers such as Modafinil, Piracetam, and Methylphenidate demonstrate promise in improving cognitive functions.; Behavioral interventions including sleep optimization, meditation, and physical exercise are evaluated for cognitive-enhancing effects.; Noninvasive brain stimulation techniques (TMS, tDCS) and innovative methods like whole-body vibration and brain-machine interfaces are explored.
Renal tubule diameter and corneal and retinal thickness increased significantly in diabetic control rats.; Noopept and insulin treatments reduced diabetes-induced pathological changes in the D + I, D + N, and D + I + N groups.; The D + I + N group showed no significant differences in renal tubule diameter and corneal and retinal thickness compared to the diabetic control group.; Noopept appears protective against diabetes-related end-organ damage in this model.
Noopept increases basal and induced DNA-binding activity of HIF-1 in SH-SH5Y cells.; Noopept stabilizes HIF1 protein by inhibiting HIF-1 prolyl hydroxylase.; Noopept alters expression of genes regulated by HIF-1 across different metabolic pathways.
Noopept normalized delayed puberty in diabetic rats (p < 0.05).; Blood glucose levels were lower in noopept-administered diabetic groups (p < 0.05).; Noopept decreased HOMA-IR in insulin-treated diabetic rats (p < 0.05).; No significant differences were found in spatial learning, kisspeptin, LH, FSH, or hippocampal NGF/BDNF levels among groups.
Intranasal Noopept after ketamine anesthesia reduces anxiety and excitability in animals.; Noopept increases animal activity and shows intensive antiamnesic effects.; Noopept improves training ability in animals.; Noopept has superior neuroprotective effects compared to piracetam and cerebrocurin.
Noopept had no effect on cell distribution across G1, S, and G2 phases.; Noopept did not change the relative level of the proliferation marker Ki-67.; The drug does not stimulate cell proliferation in the tested cell lines.
Frequently asked questions
What is Noopept?
**Mechanism of Action** Noopept (Omberacetam, GVS-111) is a synthetic proline-containing dipeptide that functions as a prodrug for cycloprolylglycine (CPG). Its primary mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and cortex, pro
How does Noopept work?
Proline-containing dipeptide prodrug of cycloprolylglycine; increases BDNF/NGF expression with nootropic and anxiolytic effects.
What is the research status of Noopept?
Noopept is currently classified as clinical trials, with 83 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of Noopept?
Noopept has a molecular weight of approximately 318.4 g/mol (formula C17H22N2O4).
Related peptides
CNTF-derived peptidergic compound that promotes neurogenesis and reduces tau pathology in preclinical Alzheimer's models.
33-aa hypothalamic neuropeptide acting on OX1/OX2 receptors to promote wakefulness and arousal.
Porcine brain-derived peptide preparation with neurotrophic-factor-like activity studied in stroke, TBI, and dementia.
NCAM-derived FG-loop peptide that activates FGFR1 to enhance synaptic plasticity and memory in animal models.
ACTH(4-10)-derived heptapeptide that elevates BDNF and modulates the melanocortin system; used clinically in Russia for stroke and cognition.
Bovine cortex-derived polypeptide complex used clinically in Eastern Europe for encephalopathy and cognitive disorders.
Build on Noopept data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key